Ride to Conquer - Homepage

Dollars at Work

Impact & Use of Funds

Since 2009, The Ride to Conquer Cancer has raised over $59 million for the BC Cancer Foundation and is B.C.’s largest cycling fundraiser.

Funds raised through The Ride to Conquer Cancer enable the BC Cancer Foundation to support life-saving cancer research and enhancements to care at the BC Cancer Agency.

The BC Cancer Foundation is the largest charitable funder of cancer research in the province, supporting leading-edge cancer research at the BC Cancer Agency that has a direct impact in improving cancer care across the province.

Funds raised through The Ride are put to use immediately, enabling life-saving research at the BC Cancer Agency, including:

  • Personalized Onco-Genomics (POG) Program: A first-of-its-kind program applying the power of genomic sequencing to clinical decision making for patients with metastatic cancer. The BC Cancer Agency’s world-leading scientists and doctors are mapping the genomic structure of each enrolled patient’s cancer to help determine potential drug targets and treatment regimens based on a biological rationale. Funds raised through The Ride are enabling the BC Cancer Agency to commence phase II of this ground-breaking program and increase the number of participants to 300.
  • Immunotherapy Research: The Ride supports the incredible momentum at the BC Cancer Agency’s Deeley Research Centre on Vancouver Island where scientists are pioneers in immunotherapy research that uses genomic approaches to generate precise and potent immune responses against cancer. The Agency is on the cusp of commencing clinical trials involving a form of immunotherapy called “adoptive T cell therapy” or ACT that will involve activating and expanding T cells in the lab and infusing large numbers of T cells into the patient’s bloodstream, once inside the bloodstream, T cells circulate throughout the body, destroying residual cancer cells wherever they are found.
  • Pediatric Genome Sequencing Project Ride dollars are supporting a project led by the BC Cancer Agency’s Dr. Poul Sorensen, which aims to expand their knowledge of rare childhood cancers. Through the sequencing of cancer genomes, they are working to find new knowledge that will lead to more effective treatments to improve and extend the lives of the youngest cancer patients.
  • Innovation Support Fund Funds raised through The Ride will support vital research equipment needs across the province, so researchers can quickly move ahead with new ideas and new research projects, without having to wait for external or national grants.
  • Lymphoid Cancer Research: With support from The Ride, the BC Cancer Agency’s Centre for Lymphoid Cancer is seeking to identify the personal genomic factors that contribute to treatment failure and discover new therapeutic combinations that will ensure success.
  • Ovarian Cancer Research (OVCARE) Program - The goal of this multidisciplinary research program is to improve the survival rates of ovarian cancer patients through improved identification, understanding, and treatment of the disease. Leaders around the world, OVCARE researchers have initiated a prevention strategy for ovarian cancer that could reduce ovarian cancer deaths by up to 50 per cent. Funds raised by Riders will be allocated to enable this research to continue.
  • Breast Cancer Research Initiative BC Cancer Agency researchers are embarking on a bold new initiative to genomically sequence each and every breast cancer patient’s tumour at the time of diagnosis, province-wide. This initiative will result in personalized strategies for patients with each of the ten unique breast cancer sub-types based on the genomic structure of their disease. It will bring more effective treatment protocols from the start of each patient’s cancer journey.

ACHIEVEMENTS TO DATE
SINCE THE RIDE BEGAN

  • Researchers created the Personalized Onco-Genomics Program, otherwise known as “POG,” to map the genomic structure of a patient’s cancer in real-time and find treatment solutions based on a biological rationale.
  • At the BC Cancer Agency’s Deeley Research Centre in Victoria, scientists have proven that T cells in the human immune system can circulate throughout the body and destroy residual cancer cells wherever they are found this research is now on the cusp of clinical trials.
  • Researchers have created new light-based devices to detect oral, cervical, skin, colorectal and lung cancers earlier.
  • Funds raised through The Ride supported the purchase of the BC Cancer Agency’s second state-of-the-art PET/CT scanner and allowed for an upgrade to the existing scanner. As a result, wait times have been reduced and the number of patients able to receive these life-saving scans have doubled;
  • Ride dollars are powering a research program in advanced cancer imaging techniques, to improve the diagnosis and monitoring of cancer so unnecessary treatments can be avoided and additional options can be identified sooner.
  • Breast cancer researchers have decoded the genetic make-up of triple negative breast cancer, proving that it is not one uniform subtype, but a complex mixture of cells.
  • Brain cancer care in B.C. has been transformed, enabling patients to be seen by neuro-oncology specialists quickly and effectively, in one visit and at one site.
  • Researchers have gained a deeper understanding of the pivotal role enzymes and proteins play in the development of childhood brain cancers and high-risk sarcomas.
  • Lung cancer researchers have begun investigating the biological basis of lung cancer and created a unique platform to screen candidate drugs for patients whose disease has become resistant.
  • Ovarian cancer researchers have made significant strides in the molecular understanding of clear cell carcinoma and the link to endometriosis, knowledge which may prevent this deadly cancer from occurring.
  • Researchers have developed an “oncopanel” to test for genetic markers that may indicate the best treatments for metastatic colorectal cancer patients.